HK1258529A1 - 用於治療神經退行性和神經炎性病症的方法和組合物 - Google Patents
用於治療神經退行性和神經炎性病症的方法和組合物Info
- Publication number
- HK1258529A1 HK1258529A1 HK19100884.8A HK19100884A HK1258529A1 HK 1258529 A1 HK1258529 A1 HK 1258529A1 HK 19100884 A HK19100884 A HK 19100884A HK 1258529 A1 HK1258529 A1 HK 1258529A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- treating neurodegenerative
- neuroinflammatory conditions
- neuroinflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562191173P | 2015-07-10 | 2015-07-10 | |
PCT/IB2016/054080 WO2017009750A1 (en) | 2015-07-10 | 2016-07-07 | Methods and compositions for treating neurodegenerative and neuroinflammatory conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1258529A1 true HK1258529A1 (zh) | 2019-11-15 |
Family
ID=57757805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100884.8A HK1258529A1 (zh) | 2015-07-10 | 2019-01-17 | 用於治療神經退行性和神經炎性病症的方法和組合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10813979B2 (zh) |
EP (1) | EP3331551B1 (zh) |
CN (1) | CN108289930A (zh) |
ES (1) | ES2882355T3 (zh) |
HK (1) | HK1258529A1 (zh) |
WO (1) | WO2017009750A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473271B1 (en) * | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
AU2015346460A1 (en) | 2014-11-10 | 2017-03-23 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
US20200339674A1 (en) * | 2017-02-17 | 2020-10-29 | The General Hospital Corporation | Methods and compositions for treating a brain injury |
WO2020152607A1 (en) * | 2019-01-22 | 2020-07-30 | St. Jude Children's Research Hospital | Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration |
WO2020197984A1 (en) * | 2019-03-22 | 2020-10-01 | Albany Medical College | Methods for improving cognitive function |
PE20230252A1 (es) | 2020-03-13 | 2023-02-07 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos de estos |
GB202015780D0 (en) * | 2020-10-05 | 2020-11-18 | Univ Bristol | Therapy |
WO2023019351A1 (en) * | 2021-08-16 | 2023-02-23 | University Health Network | Methods and compositions for treating alpha-synuclein-mediated neurodegeneration |
CN116370608B (zh) * | 2023-05-15 | 2024-04-12 | 华中科技大学 | Il-33在长期抑郁引起的记忆损伤治疗中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
WO2007130627A2 (en) * | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
US7605265B2 (en) | 2007-01-22 | 2009-10-20 | Biotechnology Research Corporation Ltd. | Heterodimers and methods of using them |
WO2008138200A1 (en) | 2007-05-11 | 2008-11-20 | Hong Kong University Of Science & Technology | Nmda and mc receptor antagonists exhibiting neuroprotective and memory enhancing activities |
US9029414B2 (en) | 2008-09-19 | 2015-05-12 | Biotechnology Research Corporation | Triterpenoid compounds and methods of use thereof |
KR101511737B1 (ko) * | 2012-12-31 | 2015-04-20 | 대한민국 | Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물 |
EP2958583B1 (en) * | 2013-02-22 | 2018-04-11 | Magic Epoch Holdings Limited | Il-33 and treatment of neurodegenerative diseases |
EP3022206B1 (en) | 2013-07-17 | 2023-07-12 | The Hong Kong University of Science and Technology | Epha4 inhibitors as neuroprotective agents |
EP3473271B1 (en) | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
-
2016
- 2016-07-07 ES ES16823957T patent/ES2882355T3/es active Active
- 2016-07-07 WO PCT/IB2016/054080 patent/WO2017009750A1/en active Application Filing
- 2016-07-07 EP EP16823957.2A patent/EP3331551B1/en active Active
- 2016-07-07 US US15/742,582 patent/US10813979B2/en active Active
- 2016-07-07 CN CN201680051169.7A patent/CN108289930A/zh active Pending
-
2019
- 2019-01-17 HK HK19100884.8A patent/HK1258529A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3331551A1 (en) | 2018-06-13 |
ES2882355T3 (es) | 2021-12-01 |
US10813979B2 (en) | 2020-10-27 |
WO2017009750A1 (en) | 2017-01-19 |
EP3331551B1 (en) | 2021-06-23 |
EP3331551A4 (en) | 2018-12-26 |
CN108289930A (zh) | 2018-07-17 |
US20190015480A1 (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259795A (en) | Methods and compositions for treating diseases associated with serpinc1 | |
HK1256602A1 (zh) | 用於治療翼狀胬肉的組合物和方法 | |
HK1258529A1 (zh) | 用於治療神經退行性和神經炎性病症的方法和組合物 | |
HK1248590A1 (zh) | 用於治療貧血的組合物和方法 | |
HK1251610A1 (zh) | 用於抑制因子d的組合物和方法 | |
IL278004A (en) | Methods and preparations for treating conditions related to aging | |
LT3250210T (lt) | Kompozicijos ir būdai, skirti gydyti cns sutrikimus | |
GB2558326B (en) | Methods and compositions for inhibiting and treating neurological conditions | |
PT3189074T (pt) | Composições e métodos para tratar e prevenir a inflamação | |
IL254963A0 (en) | Preparations and methods for the treatment of autism | |
ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
HK1256298A1 (zh) | 用於治療和預防神經退化性病症的組合物和方法 | |
EP3313387A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
PT3220908T (pt) | Composições e métodos para o tratamento da endometriose | |
GB201521083D0 (en) | Compositions for treatment and methods thereof |